论文信息 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study - 字舞流文

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

P. Ganly | S. O'brien | C. Tam | T. Robak | M. Šimkovič | A. Österborg | M. Shadman | A. Cohen | L. Qiu | A. Ferrajoli | W. Jurczak | R. Weinkove | B. Eichhorst | P. Hillmen | N. Lamanna | S. Grosicki | A. Mital | M. Kaźmierczak | H. Yimer | J. Mayer | A. Gillespie-Twardy | K. Zhou | T. Salmi | K. Wu | Jennifer R. Brown | L. Fu | Megan Wang | Jessica Li